Alcolase Raises €1.5M for Alcohol Metabolism Enzyme Technology

Alcolase, a pioneering biotech firm, has successfully closed a €1.5 million seed funding round, co-led by Ada Ventures. This significant investment will fuel the development of the company's groundbreaking enzyme system designed to metabolize alcohol within the stomach, preventing its absorption into the bloodstream. The round also saw participation from Delphinus Venture Capital, Antler, Manigoff Invest, and a cohort of angel investors, underscoring strong market confidence in Alcolase's innovative approach.

The core of Alcolase's technology lies in a novel liposomal encapsulation platform. This sophisticated system shields sensitive enzymes from the harsh acidic environment of the stomach, ensuring their efficacy at the precise location needed for alcohol breakdown. This scientific advancement holds potential applications far beyond its initial focus, positioning Alcolase as a key player in advanced drug delivery systems.

The company's initial product targets a significant unmet need, particularly within East Asian populations where a genetic variant, ALDH2 deficiency, affects an estimated 540 million individuals. This deficiency impairs the body's ability to process alcohol, leading to adverse reactions and increased long-term health risks. Alcolase's solution offers a physiological approach to managing alcohol intolerance, moving beyond symptomatic relief offered by current over-the-counter remedies.

This strategic investment aligns perfectly with Ada Ventures' 'healthy ageing' investment thesis, focusing on scientific innovations that address overlooked health challenges. The firm highlighted that ALDH2 deficiency represents a substantial health issue, affecting millions globally yet largely ignored by mainstream health innovation. The backing of Alcolase by Ada Ventures, alongside co-investors Delphinus Venture Capital, Antler, and Manigoff Invest, signals a growing recognition of the commercial and social impact of addressing such specific, yet widespread, health conditions.

The founding team, including CEO Mikkel Precht (MSc Molecular Biomedicine) and co-founder Ib Christensen (PhD Fermentation and Purification), brings a wealth of expertise from leading pharmaceutical companies like Novo Nordisk, Boehringer Ingelheim, and Xellia Pharmaceuticals. This deep scientific bench, further bolstered by CSO Henrik Almblad, has been instrumental in validating the technology. Early commercial indicators, such as letters of intent from Asian pharmaceutical and food technology firms, government support in Korea, and a user survey showing strong consumer interest and willingness to pay, further validate the market opportunity.

With the newly secured capital, Alcolase plans to advance its in vivo studies, strengthen its intellectual property portfolio, and establish its UK therapeutic subsidiary. The company is also preparing for initial commercial launches in Singapore and South Korea, markets where the need is most acute. Concurrently, the UK entity will spearhead the development of the broader enzyme delivery platform for diverse therapeutic uses, opening new avenues for growth and innovation in the life sciences sector.